Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial

Massimo Antonelli

doi:10.1186/s13063-015-0614-4

Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial

Massimo Antonelli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

13 Citazioni (Scopus)

Abstract

Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.

Lingua originale	English
pagine (da-a)	102-102
Numero di pagine	1
Rivista	Trials
Volume	16
DOI	https://doi.org/10.1186/s13063-015-0614-4
Stato di pubblicazione	Pubblicato - 2015

Keywords

Anti-Bacterial Agents
Clinical Protocols
Colistin
Drug Resistance, Multiple, Bacterial
Europe
Gram-Negative Bacterial Infections
Humans
Incidence
Patents as Topic
Pneumonia, Ventilator-Associated
Research Design
Thienamycins
Time Factors
Treatment Outcome

Accesso al documento

10.1186/s13063-015-0614-4

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint

Entra nei temi di ricerca di 'Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial'. Insieme formano una fingerprint unica.

Cita questo

Antonelli, M. (2015). Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials, 16, 102-102. https://doi.org/10.1186/s13063-015-0614-4

@article{67c755204c4e432dbe29e9fd446055d0,

title = "Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial",

abstract = "Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.",

keywords = "Anti-Bacterial Agents, Clinical Protocols, Colistin, Drug Resistance, Multiple, Bacterial, Europe, Gram-Negative Bacterial Infections, Humans, Incidence, Patents as Topic, Pneumonia, Ventilator-Associated, Research Design, Thienamycins, Time Factors, Treatment Outcome, Anti-Bacterial Agents, Clinical Protocols, Colistin, Drug Resistance, Multiple, Bacterial, Europe, Gram-Negative Bacterial Infections, Humans, Incidence, Patents as Topic, Pneumonia, Ventilator-Associated, Research Design, Thienamycins, Time Factors, Treatment Outcome",

author = "Massimo Antonelli",

year = "2015",

doi = "10.1186/s13063-015-0614-4",

language = "English",

volume = "16",

pages = "102--102",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central Ltd.",

}

Antonelli, M 2015, 'Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial', Trials, vol. 16, pagg. 102-102. https://doi.org/10.1186/s13063-015-0614-4

Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. / Antonelli, Massimo.
In: Trials, Vol. 16, 2015, pag. 102-102.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial

AU - Antonelli, Massimo

PY - 2015

Y1 - 2015

N2 - Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.

AB - Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.

KW - Anti-Bacterial Agents

KW - Clinical Protocols

KW - Colistin

KW - Drug Resistance, Multiple, Bacterial

KW - Europe

KW - Gram-Negative Bacterial Infections

KW - Humans

KW - Incidence

KW - Patents as Topic

KW - Pneumonia, Ventilator-Associated

KW - Research Design

KW - Thienamycins

KW - Time Factors

KW - Treatment Outcome

KW - Anti-Bacterial Agents

KW - Clinical Protocols

KW - Colistin

KW - Drug Resistance, Multiple, Bacterial

KW - Europe

KW - Gram-Negative Bacterial Infections

KW - Humans

KW - Incidence

KW - Patents as Topic

KW - Pneumonia, Ventilator-Associated

KW - Research Design

KW - Thienamycins

KW - Time Factors

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/71966

U2 - 10.1186/s13063-015-0614-4

DO - 10.1186/s13063-015-0614-4

M3 - Article

SN - 1745-6215

VL - 16

SP - 102

EP - 102

JO - Trials

JF - Trials

ER -